Unique ID issued by UMIN | UMIN000027161 |
---|---|
Receipt number | R000030924 |
Scientific Title | TOPICal Steroid versus placebo for the prevention of radiation dermatitis in head and neck cancer patients receiving chemoradiotherapy : a phase III, randomized, double-blinded trial |
Date of disclosure of the study information | 2017/05/01 |
Last modified on | 2017/11/13 16:25:23 |
TOPICal Steroid versus placebo for the prevention of radiation dermatitis
in head and neck cancer patients receiving chemoradiotherapy
: a phase III, randomized, double-blinded trial
TOPICS study(J-SUPPORT 1602)
TOPICal Steroid versus placebo for the prevention of radiation dermatitis
in head and neck cancer patients receiving chemoradiotherapy
: a phase III, randomized, double-blinded trial
TOPICS study(J-SUPPORT 1602)
Japan |
Locally Advanced Squamous Cell Carcinoma of the Head and Heck
Medicine in general | Oto-rhino-laryngology | Radiology |
Malignancy
NO
To clarify the prophylactic effect of topical steroid for radiation dermatitis in SCCHN patients receiving hcemoradiotherapy
Efficacy
Confirmatory
Phase III
The frequency of radiation dermatitis grade2
The frequency of radiation dermatitis grade2
Treatment comliance
The frequency of local infection
The duration of grade2/3/4 radiation dermatitis
the rate of radiation dermatitis grade 2 at 2weeks after the end of radiotherapy
Toxicties(including PRO-CTCAE)
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Placebo
YES
YES
Institution is considered as adjustment factor in dynamic allocation.
YES
No need to know
2
Treatment
Medicine |
Basic nursing care with Topical steroid
Start:develop to Grade 1 radiation dermatitis or recieced 30Gy of RT
Finish:Improved to Grade 1 radiation dermatitis or 8 weeks after start of this treatmen
Basic nursing care with Topical placebo
Start:develop to Grade 1 radiation dermatitis or recieced 30Gy of RT
Finish:Improved to Grade 1 radiation dermatitis or 8 weeks after start of this treatment
20 | years-old | <= |
80 | years-old | >= |
Male and Female
*PS 0-1
*Have a plan to receive CRT,CDDP/RT
*Have a plan to receive >66Gy radiotherapy
*Have a plan to receive >200mg/m2 CDDP during RT
*No diseases related with dermatitis
*Written in informed consent
Received steroid therapy before this treatment
Have an infection
Have allergies to Vaseline or topical steroid
Have severe complications
220
1st name | |
Middle name | |
Last name | Sadamoto Zenda |
National Cancer Center Hospital East
Department of Radiation Oncology
6-5-1 Kashiwanoha Kashiwa Chiba, Japan
04-7133-1111
szenda@east.ncc.go.jp
1st name | |
Middle name | |
Last name | Sadamoto Zenda |
National Cancer Center Hospital East
Department of Radiation Oncology
6-5-1 Kashiwanoha Kashiwa Chiba, Japan
04-7133-1111
szenda@east.ncc.go.jp
Department of Radiation Oncology, National Cancer Center Hospital East
The National Cancer Center Research and Development Fund ( 27-A-3)
Japanese Governmental office
Japan
Project Mirai Cancer Research Grants
NO
2017 | Year | 05 | Month | 01 | Day |
Unpublished
Open public recruiting
2017 | Year | 04 | Month | 27 | Day |
2017 | Year | 05 | Month | 07 | Day |
2017 | Year | 04 | Month | 27 | Day |
2017 | Year | 11 | Month | 13 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000030924
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |